[{"address1": "217 Queen Street West", "address2": "Suite 301", "city": "Toronto", "state": "ON", "zip": "M5V 0R2", "country": "Canada", "website": "https://awaknlifesciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprietary S\u0096ketamine oral thin film, and manualized relapse prevention CBT to treat AUD; and MDMA/Zydis, an investigational medicinal product entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine, and dopamine. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD; with Graft Polymer (UK) PLC to develop chemical entity series programme for trauma-related mental health disorders; and with the University of Nottingham focusing on evaluating the company's lead aminoindane series and its potential to enhance social cognition and pro-social behaviors. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.", "fullTimeEmployees": 6, "companyOfficers": [{"maxAge": 1, "name": "Mr. George  Scorsis", "age": 47, "title": "Co-founder & Chairman of the Board", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Tennyson", "title": "Co-founder, President, CEO & Director", "fiscalYear": 2024, "totalPay": 185116, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan James Held C.A., CPA, CA", "age": 38, "title": "Co-founder, CFO, Chief Business Officer & Secretary", "yearBorn": 1986, "fiscalYear": 2024, "totalPay": 108597, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. David John Nutt DM, FMedSci, FRCP, FRCPsych, FSB, Ph.D.", "title": "Chair of Pre-Clinical & Clinical Advisory Board and Chief Research Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.08, "open": 0.08, "dayLow": 0.08, "dayHigh": 0.08, "regularMarketPreviousClose": 0.08, "regularMarketOpen": 0.08, "regularMarketDayLow": 0.08, "regularMarketDayHigh": 0.08, "payoutRatio": 0.0, "beta": 2.601, "forwardPE": -0.27083334, "volume": 35, "regularMarketVolume": 35, "averageVolume": 0, "averageVolume10days": 0, "averageDailyVolume10Day": 0, "bid": 0.075, "ask": 0.08, "bidSize": 0, "askSize": 0, "marketCap": 2742025, "fiftyTwoWeekLow": 0.04872, "fiftyTwoWeekHigh": 0.1334, "priceToSalesTrailing12Months": 47.970207, "fiftyDayAverage": 0.065, "twoHundredDayAverage": 0.0719695, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2202220, "profitMargins": 0.0, "floatShares": 36503541, "sharesOutstanding": 41662600, "heldPercentInsiders": 0.10227, "heldPercentInstitutions": 0.0, "impliedSharesOutstanding": 42185000, "bookValue": -0.037, "lastFiscalYearEnd": 1706659200, "nextFiscalYearEnd": 1738281600, "mostRecentQuarter": 1730332800, "netIncomeToCommon": -2597354, "trailingEps": -0.06, "forwardEps": -0.24, "enterpriseToRevenue": 38.527, "enterpriseToEbitda": -0.917, "52WeekChange": -0.1875, "SandP52WeekChange": 0.16932249, "quoteType": "EQUITY", "currentPrice": 0.065, "recommendationKey": "none", "totalCash": 505850, "totalCashPerShare": 0.012, "ebitda": -2402206, "totalDebt": 0, "quickRatio": 0.263, "currentRatio": 0.29, "totalRevenue": 57161, "revenuePerShare": 0.002, "returnOnAssets": -1.7198199, "grossProfits": 57161, "freeCashflow": -795152, "operatingCashflow": 2251778, "revenueGrowth": -0.873, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -128.5654, "financialCurrency": "CAD", "symbol": "AWKNF", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "marketState": "CLOSED", "cryptoTradeable": false, "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1627997400000, "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.065, "corporateActions": [], "regularMarketTime": 1748376000, "shortName": "Awakn Life Sciences Corp.", "longName": "Awakn Life Sciences Corp.", "exchange": "PNK", "messageBoardId": "finmb_673256170", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChange": 0.0, "regularMarketDayRange": "0.08 - 0.08", "fullExchangeName": "OTC Markets OTCPK", "averageDailyVolume3Month": 0, "fiftyTwoWeekLowChange": 0.01628, "fiftyTwoWeekLowChangePercent": 0.33415434, "fiftyTwoWeekRange": "0.04872 - 0.1334", "fiftyTwoWeekHighChange": -0.068399996, "fiftyTwoWeekHighChangePercent": -0.5127436, "fiftyTwoWeekChangePercent": -18.75, "epsTrailingTwelveMonths": -0.06, "epsForward": -0.24, "fiftyDayAverageChange": 0.0, "fiftyDayAverageChangePercent": 0.0, "twoHundredDayAverageChange": -0.006969504, "twoHundredDayAverageChangePercent": -0.09683969, "priceToBook": -1.7567567, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "displayName": "Solvonis Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-07-26"}]